PG
ABMD

Pendal Group’s Abiomed Inc ABMD Stock Holding History

Pendal Group’s Portfolio ABMD Stock Details ABMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-7,875
Closed -$2.25M – 480
2019
Q1 		$2.25M Sell
7,875
-7,207
-48% -$2.4M 0.03% 198
2018
Q4 		$4.9M Sell
15,082
-26,475
-64% -$9.2M 0.08% 130
2018
Q3 		$18.7M Buy
41,557
+20,087
+94% +$7.92M 0.25% 68
2018
Q2 		$8.78M Buy
+21,470
New +$7.78M 0.11% 120

Other funds holding ABMD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
AAMU
Amundi Asset Management US Boston, Massachusetts $131B AUM 73.57% 1-Year Est. Return

Pendal Group's ABMD Position: Q2 2019 in Review

Pendal Group sold out of Abiomed Inc (ABMD) in Q2 2019, closing a stake of 7,875 shares — an estimated $2.25M sold.

Pendal Group first reported a position in ABMD in Q2 2018 and held it in 4 quarters. The position peaked at $18.7M in Q3 2018. 484 funds tracked by Wall St. Rank hold ABMD as of Q2 2019.

  • Pendal Group reported no remaining Abiomed Inc position as of Q2 2019 after selling out during the quarter.
  • Pendal Group sold 7,875 Abiomed Inc shares in Q2 2019, an estimated $2.25M.
  • Pendal Group first reported a position in Abiomed Inc in Q2 2018 and held it in 4 quarters.
  • Pendal Group's Abiomed Inc position peaked at $18.7M in Q3 2018.
  • 484 funds tracked by Wall St. Rank held Abiomed Inc as of Q2 2019.

Based on Pendal Group's 13F filing for Q2 2019, filed 1 Aug 2019.